Daniel M Witt1, Thomas Delate2, Elaine M Hylek3, Nathan P Clark2, Mark A Crowther4, Francesco Dentali5, Walter Ageno5, Kerri D Martinez6, David A Garcia7. 1. Kaiser Permanente Colorado, Aurora, CO; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Denver, CO. Electronic address: dan.m.witt@kp.org. 2. Kaiser Permanente Colorado, Aurora, CO; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Denver, CO. 3. Boston University School of Medicine, Boston, MA. 4. McMaster University, Hamilton, Canada. 5. University of Insubria, Varese, Italy. 6. Kaiser Permanente Colorado, Aurora, CO. 7. University of Washington, Seattle, WA.
Abstract
INTRODUCTION: Avoiding intracranial hemorrhage (ICH) during warfarin therapy is critical but little is known about factors that affect warfarin-related ICH outcomes. We aimed to define the impact of warfarin on ICH incidence rates and to identify baseline clinical characteristics of patients who experienced ICH and factors associated with fatal ICH. MATERIALS AND METHODS: The primary outcome of this retrospective cohort study was the incident ICH rate per 10,000 person-years for patients receiving and not receiving warfarin therapy. Cox proportional hazards modeling was used to adjust for potential confounding factors in assessment of the association of warfarin with fatal ICH. RESULTS: A total of 1348 patients with incident ICH, 259 (19%) who were receiving warfarin therapy, were included. The incident ICH rates were 74/10,000 (warfarin) and 5/10,000 (non-warfarin) person-years (p<0.001). Warfarin patients were older and carried a higher burden of chronic disease. The unadjusted hazard ratio (HR) for fatal ICH was 1.64 (95% confidence interval [CI] 1.31-2.05) for warfarin patients compared to non-warfarin patients. However, the HR was no longer significant after adjustment for confounding variables (1.10; 95% CI 0.84-1.42). An INR greater than 3.5 at presentation doubled the adjusted risk for fatal ICH with warfarin therapy. Subarachnoid and subdural ICHs were less likely to be fatal than other ICH types, and each year increase in age was associated with 4% increased risk of fatal ICH. CONCLUSIONS: Although warfarin use increases the rate of incident ICH, other factors impact the risk of fatal ICH, even among anticoagulated patients.
INTRODUCTION: Avoiding intracranial hemorrhage (ICH) during warfarin therapy is critical but little is known about factors that affect warfarin-related ICH outcomes. We aimed to define the impact of warfarin on ICH incidence rates and to identify baseline clinical characteristics of patients who experienced ICH and factors associated with fatal ICH. MATERIALS AND METHODS: The primary outcome of this retrospective cohort study was the incident ICH rate per 10,000 person-years for patients receiving and not receiving warfarin therapy. Cox proportional hazards modeling was used to adjust for potential confounding factors in assessment of the association of warfarin with fatal ICH. RESULTS: A total of 1348 patients with incident ICH, 259 (19%) who were receiving warfarin therapy, were included. The incident ICH rates were 74/10,000 (warfarin) and 5/10,000 (non-warfarin) person-years (p<0.001). Warfarinpatients were older and carried a higher burden of chronic disease. The unadjusted hazard ratio (HR) for fatal ICH was 1.64 (95% confidence interval [CI] 1.31-2.05) for warfarinpatients compared to non-warfarinpatients. However, the HR was no longer significant after adjustment for confounding variables (1.10; 95% CI 0.84-1.42). An INR greater than 3.5 at presentation doubled the adjusted risk for fatal ICH with warfarin therapy. Subarachnoid and subdural ICHs were less likely to be fatal than other ICH types, and each year increase in age was associated with 4% increased risk of fatal ICH. CONCLUSIONS: Although warfarin use increases the rate of incident ICH, other factors impact the risk of fatal ICH, even among anticoagulated patients.
Authors: Alessandro Biffi; Joji B Kuramatsu; Audrey Leasure; Hooman Kamel; Christina Kourkoulis; Kristin Schwab; Alison M Ayres; Jordan Elm; M Edip Gurol; Steven M Greenberg; Anand Viswanathan; Christopher D Anderson; Stefan Schwab; Jonathan Rosand; Fernando D Testai; Daniel Woo; Hagen B Huttner; Kevin N Sheth Journal: Ann Neurol Date: 2017-10-31 Impact factor: 10.422
Authors: Derek H W Little; Rinku Sutradhar; Joshua O Cerasuolo; Richard Perez; James Douketis; Anne Holbrook; J Michael Paterson; Tara Gomes; Deborah M Siegal Journal: CMAJ Date: 2021-03-01 Impact factor: 8.262
Authors: Alessandro Biffi; Sebastian Urday; Patryk Kubiszewski; Lee Gilkerson; Padmini Sekar; Axana Rodriguez-Torres; Margaret Bettin; Andreas Charidimou; Marco Pasi; Christina Kourkoulis; Kristin Schwab; Zora DiPucchio; Tyler Behymer; Jennifer Osborne; Misty Morgan; Charles J Moomaw; Michael L James; Steven M Greenberg; Anand Viswanathan; M Edip Gurol; Bradford B Worrall; Fernando D Testai; Jacob L McCauley; Guido J Falcone; Carl D Langefeld; Christopher D Anderson; Hooman Kamel; Daniel Woo; Kevin N Sheth; Jonathan Rosand Journal: Stroke Date: 2020-06-10 Impact factor: 10.170